Tarsus Medical Affairs

Our Medical Affairs team is a peer-based resource for healthcare providers. We are committed to advancing science and medicine through awareness, education, and research.

Our Senior Medical Ambassadors (SMAs) are field-based scientific and medical peers, empowered to serve healthcare providers.

SMA Access — find a scientifically trained Tarsus field medical professional near you.

Tarsus supports investigator-initiated trial ideas

As part of our commitment to advancing science and medicine, Tarsus believes in supporting independent and ethical clinical research, designed and conducted by qualified third-party investigators.

Clinical study proposals must offer new and meaningful scientific evidence and qualify for institutional review board (IRB) approval.

Qualified investigators can submit an unsolicited research abstract aligned with the following strategic areas of interest using this short request form.

Strategic areas of interest:

  • Demodex blepharitis
  • Lyme disease
  • Meibomian gland dysfunction (MGD)
  • Rosacea

To be considered for review, the proposal must include study objectives, end points, hypotheses, and a short abstract.

For more information about our Investigator-Initiated Trial program, please contact your Senior Medical Ambassador.

Tarsus provides support for independent medical education grants

Tarsus recognizes the importance of independent medical education and provides financial support for accredited and nonaccredited professional education for US healthcare providers. It is important to note that Tarsus does not assume responsibility for the following:

  • The development of content
  • Faculty selection
  • Venue selection
  • Methods that ensure educational effectiveness
  • Methods that ensure the meeting of compliance and regulatory requirements
  • Submission for accredited continuing education (CE)
    programs

To submit a grant request, please complete the form or upload a file detailing the date(s), location(s), proposed audience, format/activity, educational objectives, and budget requested.

Please ensure that your organization can be classified as one of the following:

  • Academic medical center or university
  • Professional society/association
  • Medical education provider (can be accredited or nonaccredited)
  • Hospital or clinic

Tarsus is currently considering support of independent medical education programs that focus on Demodex blepharitis.

Contact the Medical Affairs team

Tarsus is committed to providing high-quality and consistent medical information. We recognize the importance of having access to trusted, accurate, and balanced clinical and scientific information about our investigational products.

Use this form to contact the Medical Affairs team with any questions you may have.

Resources

Explore Tarsus-supported works by using this repository of publications and conference materials


TP-03 (lotilaner ophthalmic solution, 0.25%) is an investigational product that is not FDA approved. Safety and efficacy have not been established by health authorities.

Clinical Ophthalmology

September 2022

Psychosocial Impact of Demodex Blepharitis

Abstract

Purpose: To evaluate the impact of Demodex blepharitis on patients’ daily activities and quality of life.

Ocular Immunology and Inflammation

August 2022

Treatment of Demodex Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle

Abstract

Purpose: To evaluate the efficacy and safety of lotilaner ophthalmic solution, 0.25% eyedrops compared to vehicle for the treatment of Demodex blepharitis.

Cornea

May 2022

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)

Abstract

Purpose: The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis.

Clinical Ophthalmology

April 2022

The Prevalence of Demodex Blepharitis in US Eye Care Clinic Patients as Determined by Collarettes: A Pathognomonic Sign

Abstract

Purpose: To evaluate the prevalence of Demodex blepharitis by its pathognomonic sign, collarettes, in patients presenting for any reason to eye care clinics in the United States.

Journal of Ophthalmology

September 2021

Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study

Abstract

Purpose: To evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis.

Contact Lens & Anterior Eye

August 2021

Safety and Efficacy of Lotilaner Ophthalmic Solution, 0.25% for the Treatment of Blepharitis Due to Demodex Infestation: A Randomized, Controlled, Double-Masked Clinical Trial

Abstract

Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to Demodex infestation compared to vehicle control.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

January 2021

Collarette Elimination and Demodex Mite Eradication with Topical Lotilaner Ophthalmic Solution, 0.25%

Abstract

Purpose: To evaluate the efficacy of topical lotilaner ophthalmic solution, 0.25%, in patients with Demodex blepharitis.

Presented at ARVO 2022

August 2022

Impact of Demodex Blepharitis on Patients and the Healthcare System: Results from the Atlas Continuation Study

Abstract

Purpose: Further evaluate the clinical impact of Demodex blepharitis.

PRESENTED AT ASCRS 2022

April 2022

Demodex Blepharitis and Coexisting Bacterial Burden in Eye Care Patients: The Pandora Study

Abstract

Purpose: Evaluate the bacterial composition on the eyelid margin of patients with and without collarettes.